検索結果

ctivity. We sincerely hope that Avarept® will contribute to improving symptoms in the many patients suffering from DED.” Senju is committed to contributing to treatments that improve patients’ quality...

Product Development Policy | Research & Development | SENJU Pharmaceutica

atter condition is rare in Japan and generally known as a rare disease, yet there are many patients suffering from it worldwide and it is known as the most common hereditary corneal diseasesup#5,6. Cu...

Research and Development System | Research & Development | SENJU Pharmaceutica

is to look toward the future and swiftly deliver innovative drugs that are truly needed by patients suffering from diseases. Hideki Tokushige, Executive Officer, General Manager, Drug Discovery Resear...

ctivity. We sincerely hope that Avarept® will contribute to improving symptoms in the many patients suffering from DED.” Senju is committed to contributing to treatments that improve patients’ quality...